US Stem Cell Inc (USRM)

[4toSchool]

The Last Futurist
Artificial Intelligence of Everything

Top Biotech Penny Stock of January 2021

Top Biotech Penny Stock of January 2021[/tag]At the Last Futurist we make stock picks, but do your own due diligence. One stock on the OTC we like is called U.S. Stem Cell, Inc. ($USRM). This stock is up over 800% in the last five days according to Barchart.com.

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. They have around 10 employees, and are currently worth $0.06.

They have had a run from $0.01 to $0.06 but it’s our conviction the stock is worth around $0.12.

Some retail investors consider it a lottery ticket to $2.00 from .05 based upon a court case (January 12th, 2021).

Today on January 5th, it’s up about another 60%. It’s at about 10x volume of an ordinary day for the stock.

Check out its website here.

They are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

They want to be pioneers of regenerative medicine / cellular therapeutics that will play a large role in positively changing the natural history of diseases ultimately, and they contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Do note that the company is delinquent with their SEC filing. This is the very definition of a high-risk OTC stock. However the company was founded in Florida in 1999, so have had time to mature.

Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells or cells from a patient’s body for enhancing cardiac function in chronic heart failure patients. They claim to be a leader in stem cell multi-therapies.

The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015 and seems fairly innovative with MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients and, MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure.

Verdict: This stock should bounce around between $0.02 and $0.05 but should eventually hit around $0.10.

We will update this post.